Actinium Pharmaceuticals (ATNM) Notes Payables (2010 - 2024)
Actinium Pharmaceuticals (ATNM) posted quarterly Notes Payables of $7.5 million for Q1 2024, up 2.11% year-over-year from $7.4 million in Q2 2023, and down 5.53% quarter-over-quarter from $8.0 million in Q4 2023.
Actinium Pharmaceuticals (ATNM) Notes Payables (2010 - 2024) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Notes Payables for 15 consecutive years, with $7.5 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Notes Payables rose 2.11% year-over-year to $7.5 million; the TTM figure through Mar 2024 stood at $7.5 million (up 2.11% YoY), while the FY2023 annual figure was $8.0 million, down 21.49% from the prior year.
- Notes Payables retreated to $7.5 million in Q1 2024 per ATNM's latest filing, from $8.0 million in the prior quarter.
- Across five years, Notes Payables topped out at $10.1 million in Q4 2022 and bottomed at $38000.0 in Q3 2020.
- Historically, Notes Payables has averaged $5.6 million across 5 years, with a median of $5.7 million in 2021.
- Annual changes were most pronounced in 2021 — Notes Payables surged 9828.95% — and 2023, when it dropped 21.49%.
- Actinium Pharmaceuticals' Notes Payables stood at $4.3 million in 2020, then gained by 27.53% to $5.5 million in 2021, then jumped by 83.02% to $10.1 million in 2022, then retreated by 21.49% to $8.0 million in 2023, then declined by 5.53% to $7.5 million in 2024.
- Business Quant data shows ATNM's Notes Payables at $7.5 million in Q1 2024, $8.0 million in Q4 2023, and $8.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 7.51 Mn |
| Dec 31, 2023 | 7.95 Mn |
| Sep 30, 2023 | 8.15 Mn |
| Jun 30, 2023 | 8.64 Mn |
| Mar 31, 2023 | 7.36 Mn |
| Dec 31, 2022 | 10.13 Mn |
| Sep 30, 2022 | 7.87 Mn |
| Jun 30, 2022 | 5.77 Mn |
| Mar 31, 2022 | 5.26 Mn |
| Dec 31, 2021 | 5.54 Mn |
| Sep 30, 2021 | 3.77 Mn |
| Jun 30, 2021 | 3.43 Mn |
| Mar 31, 2021 | 3.73 Mn |
| Dec 31, 2020 | 4.34 Mn |
| Sep 30, 2020 | 38,000.00 |
| Jun 30, 2020 | 154,000.00 |
| Dec 31, 2019 | 381,000.00 |
| Sep 30, 2019 | 25,331.00 |
| Jun 30, 2019 | 100,777.00 |
| Mar 31, 2019 | 175,410.00 |